摘要:
A compound of the formula (I) in which R1 is —OR11, —SR11, —SOR11, —SO2R11, —NHR11, or —NR12R13 , and R11, R12, and R13 are as defined broadly in the text. R2 is H, C1-C6alkyl, carbamoyl, or an ester group. R3 is thienyl, pyridyl optionally substituted by halogen or C1-C6alkoxy; naphthyl optionally substituted by C1-C6alkoxy; dioxane fused phenyl; dioxacyclopentane fused phenyl; or optionally substituted phenyl. Y is CH or N. A process for preparing such compounds, pharmaceutical compositions containing such compounds, and a method of treating asthma using them are also disclosed and claimed.
摘要翻译:其中R 1为-OR 11,-SR 11,-SOR 11的式(I)化合物, SO 2,-SO 2,R 11,-NHR 11或-NR 12 R 13 < / SUP>和R 11,R 12和R 13如在文中广义地定义的。 R 2是H,C 1 -C 6烷基,氨基甲酰基或酯基。 R 3是噻吩基,任选被卤素或C 1 -C 6烷氧基取代的吡啶基; 任选被C 1 -C 6烷氧基取代的萘基; 二恶烷稠合苯基; 二氧杂环戊烷稠合苯基; 或任选取代的苯基。 Y是CH或N.一种制备这种化合物的方法,含有这些化合物的药物组合物和使用它们治疗哮喘的方法也被公开和要求保护。
摘要:
N-(4-Aminophenol) prolineamide and cosmetically acceptable salts thereof are useful as primary intermediates in oxidative hair dyeing. Compositions which contain a hair dye produced by oxidatively coupling N-(4-aminophenol) prolineamide with a coupler in the presence of an oxidizing agent are applied to the hair in oxidative hair dyeing processes.
摘要:
The present invention provides pharmaceutical compositions and methods for treating certain conditions comprising administering an amount of a compound or composition of the invention which is effective to inhibit the activity of at least one matrix metalloprotease, resulting in achievement of the desired effect. The compounds of the present invention are of the generalized formula ##STR1## where v is 1, 2, 3 or 4 and Ar represents a substituted aromatic moiety. These compounds are useful for inhibiting matrix metalloproteases and, therefore, combating conditions to which MMP's contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, corneal ulceration, proteinuria, aneurysmal aortic disease, dystrophobic epidermolysis, bullosa, conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempero mandibular joint disease, demyelating diseases of the nervous system, tumor metastasis or degenerative cartilage loss following traumatic joint injury, and coronary thrombosis from atherosclerotic plaque rupture. The present invention also provides pharmaceutical compositions and methods for treating such conditions.